Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus irinotecan versus irinotecan in refractory small-cell lung cancer
ChiCTR2000037396Phase 4Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab and irinotecan in small cell lung cancer (SCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Objective response rate. Started Oct 2020; status: recruiting.
02
Drugs
pembrolizumabirinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000037396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037396.